(Q38075878)

28 August 2017

1 reference

title

Systemic lupus erythematosus: an update on current pharmacotherapy and future directions (English)

1 reference

systemic lupus erythematosus

28 August 2017

0 references

1 reference

3

Dafna D Gladman

1 reference

28 August 2017

Zahi Touma

1

1 reference

28 August 2017

Murray B Urowitz

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

23 January 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

723-737

1 reference

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Pharmacotherapy of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Combined oral contraceptives in women with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Lifetime trajectory of physical activity according to energy expenditure and joint force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Abetimus sodium: a medication for the prevention of lupus nephritis flares

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

SLEDAI-2K for a 30-day window.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764411

10.1517/14712598.2013.764411

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference